Acrivastine

Acrivastine (BW825C) is a short acting histamine 1 receptor antagonist for the treatment of allergic rhinitis.

Product Specifications

CAS Number

[87848-99-5]

Product Name Alternative

BW825C

UNSPSC

12352005

Hazard Statement

H413

Target

Histamine Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Endocrinology

Assay Protocol

https://www.medchemexpress.com/Acrivastine.html

Concentration

10mM

Purity

99.59

Solubility

DMSO : 50 mg/mL (ultrasonic) |H2O : 1 mg/mL (ultrasonic; warming; heat to 80°C)

Smiles

O=C(O)/C=C/C1=NC(/C(C2=CC=C(C)C=C2)=C/CN3CCCC3)=CC=C1

Molecular Formula

C22H24N2O2

Molecular Weight

348.44

Precautions

H413

References & Citations

[1]Brogden RN, et al. Acrivastine. A review of its pharmacological properties and therapeutic efficacy in allergic rhinitis, urticaria and related disorders. Drugs. 1991 Jun;41 (6) :927-40.|[2]Gibbs TG, et al. Acrivastine in two doses compared with placebo in a multicentre, parallel group study for the treatment of seasonal allergic rhinitis. Br J Clin Pract. 1989 Jan;43 (1) :11-4.